文献类型：期刊文献

英文题名：Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management

作者：Ma, Cheng-Xu[1,2];Ma, Xiao-Ni[1,2];Guan, Cong-Hui[1,2];Li, Ying-Dong[3];Mauricio, Didac[4];Fu, Song-Bo[1,2]

第一作者：Ma, Cheng-Xu

通信作者：Fu, SB[1];Mauricio, D[2]

机构：[1]Lanzhou Univ, Hosp 1, Dept Endocrinol, 1 West Donggang Rd, Lanzhou 730000, Gansu, Peoples R China;[2]Lanzhou Univ, Clin Med Coll 1, Lanzhou 730000, Gansu, Peoples R China;[3]Gansu Univ Chinese Med, Coll Integrated Tradit Chinese & Western Med, Lanzhou 730000, Gansu, Peoples R China;[4]Autonomous Univ Barcelona, Hosp Santa Creu Sant Pau, Dept Endocrinol & Nutr, CIBER Diabet & Associated Metab Dis CIBERDEM, Barcelona 08041, Spain

第一机构：Lanzhou Univ, Hosp 1, Dept Endocrinol, 1 West Donggang Rd, Lanzhou 730000, Gansu, Peoples R China

通信机构：[1]corresponding author), Lanzhou Univ, Hosp 1, Dept Endocrinol, 1 West Donggang Rd, Lanzhou 730000, Gansu, Peoples R China;[2]corresponding author), Autonomous Univ Barcelona, Hosp Santa Creu Sant Pau, Dept Endocrinol & Nutr, CIBER Diabet & Associated Metab Dis CIBERDEM, Barcelona 08041, Spain.

年份：2022

卷号：21

期号：1

外文期刊名：CARDIOVASCULAR DIABETOLOGY

收录：;Scopus(收录号：2-s2.0-85130041369);WOS:【SCI-EXPANDED(收录号:WOS:000796062200003)】；

基金：The authors disclose receipt of the following forms of financial support for the research, authorship, and publication of this article: this work was supported by grants from the Lanzhou Chengguan District Science and Technology Plan Project (2021-9-19), the Hospital Fund of the First Hospital of Lanzhou University (ldyyyn2020-93), the Construction Program of Gansu Provincial Clinical Medical Research Center for Endocrine Diseases (20JR10FA667), the Gansu Provincial Natural Science Foundation (20JR10RA681), and the Special Funds of Science and Technology Development of the Chinese Central Government to Guide Local in 2020 (1004TCYA032).

语种：英文

外文关键词：Type 2 diabetes mellitus; Cardiovascular diseases; Hyperlipidemia; Hypertension; Therapy principle; Antidiabetic therapy

摘要：Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2 diabetes mellitus (T2DM), particularly in low- and middle-income countries. To effectively prevent the development of CVDs in T2DM, considerable effort has been made to explore novel preventive approaches, individualized glycemic control and cardiovascular risk management (strict blood pressure and lipid control), together with recently developed glucose-lowering agents and lipid-lowering drugs. This review mainly addresses the important issues affecting the choice of antidiabetic agents and lipid, blood pressure and antiplatelet treatments considering the cardiovascular status of the patient. Finally, we also discuss the changes in therapy principles underlying CVDs in T2DM.